Cevdet Samikoglu

Cevdet Samikoglu has extensive experience in the biotechnology, financial, and investment sectors. Cevdet started their career at Goldman Sachs in 1992, where they served as the Director of Research in Special Situations Investing for over ten years. In 2003, they co-founded Greywolf Capital Management, where they held the roles of Co-Founder and Co-Portfolio Manager until 2010. Since 2012, Cevdet has been involved with Biosplice Therapeutics, initially joining as Chief Financial Officer and later taking on the roles of President and Chief Financial Officer. Currently, they serve as the Chief Executive Officer of Biosplice Therapeutics, contributing to the development of small-molecule therapeutics based on alternative pre-mRNA splicing.

Cevdet Samikoglu completed their education with a Master of Business Administration (MBA) degree from Harvard Business School, which they attended from 1995 to 1997. Prior to that, they earned a Bachelor of Arts (B.A.) degree in Economics from Hamilton College, where they studied from 1989 to 1992. Cevdet Samikoglu also obtained a High School Diploma from Robert College, where they studied from 1982 to 1989.